Thursday, July 8, 2021
HomeHealthcareNovavax Covid-19 vaccine shows 90% efficacy, protection against variants

Novavax Covid-19 vaccine shows 90% efficacy, protection against variants

The results make Novavax the newest vaccine designer to post favorable data in a big, pivotal research study. The information readout has actually been extremely expected, as the vaccine’s stability at standard refrigerator temperature levels makes it much easier to distribute and store in more parts of the world compared to the messenger RNA-based vaccines, which need ultra-freezing temperature levels. Novavax conducted the Phase 3 test of its vaccine with assistance from the U.S. government, consisting of the Biomedical Advanced Research and Development Authority, which is supplying up to$1.74 billion under a Department of Defense agreement.

The results make Novavax the most current vaccine developer to post favorable data in a large, essential research study. The data readout has been highly expected, as the vaccine’s stability at basic refrigerator temperatures makes it simpler to store and disperse in more parts of the world compared to the messenger RNA-based vaccines, which need ultra-freezing temperatures. Novavax assessed its vaccine in a placebo-controlled Phase 3 study enrolling almost 30,000 clients in the U.S. and Mexico. Novavax reported that its vaccine was usually well endured by patients. Novavax carried out the Phase 3 test of its vaccine with assistance from the U.S. government, consisting of the Biomedical Advanced Research and Development Authority, which is supplying up to$1.74 billion under a Department of Defense contract.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments